DOCSLIB.ORG

Dissertation Submitted to the Combined Faculties for the Natural

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dissertation Submitted to the Combined Faculties for the Natural Dissertation submitted to the Combined Faculties for the Natural Sciences and for Mathematics of the Ruperto Carola University of Heidelberg, Germany for the degree of Doctor of Natural Sciences Presented by M.Sc. Emre Sofyali born in: Edirne, Turkey Oral examination: 09.09.2019 GLYATL1 PROMOTES ENDOCRINE THERAPY RESISTANCE IN BREAST CANCER Referees: Prof. Dr. Stefan Wiemann PD Dr. rer. nat. Karin Müller-Decker Declaration of Authorship I hereby declare that the work presented in my dissertation was carried out between August 2015 and July 2019 under the supervision of Prof. Dr. Stefan Wiemann in the group of Molecular Genome Analysis at the German Cancer Research Center (DKFZ, Heidelberg, Germany). If not stated differently and referenced within the text, the data described in my dissertation is original, has been gathered by myself and has not yet been presented as a part of a university examination. All main sources, as well as the work of joint cooperation have been referenced appropriately. I, as author, hereby declare no potential conflict of interest. Heidelberg, Emre Sofyali Table of Contents Summary ......................................................................................................................................... 1 Zusammenfassung ........................................................................................................................... 3 1. Introduction ............................................................................................................................. 5 1.1 Breast Cancer ................................................................................................................... 5 1.1.1 Molecular Subtypes of Breast Cancer .......................................................................... 5 1.1.2 Endocrine Therapy ...................................................................................................... 8 1.2 Epigenetics ..................................................................................................................... 14 1.2.1 DNA methylation ....................................................................................................... 14 1.2.2 Histone modifications ................................................................................................. 16 1.3 CRISPR/dCas9-mediated Epigenetic Editing ................................................................ 21 2. Aims ....................................................................................................................................... 25 3. Materials and Methods .......................................................................................................... 27 3.1 Materials ......................................................................................................................... 27 3.1.1 Instruments ................................................................................................................. 27 3.1.2 Chemicals and Reagents ............................................................................................. 28 3.1.3 Assay Kits ................................................................................................................... 30 3.1.4 Consumables ............................................................................................................... 31 3.1.5 Software ...................................................................................................................... 32 3.1.6 Database ...................................................................................................................... 33 3.1.7 Buffers and solutions .................................................................................................. 33 3.1.8 Antibodies ................................................................................................................... 34 3.1.9 siRNAs........................................................................................................................ 34 3.1.10 Primers .................................................................................................................... 35 3.2 Methods .......................................................................................................................... 36 3.2.1 Cell Culture and Growth Conditions .......................................................................... 36 3.2.2 siRNA Transfections .................................................................................................. 38 3.2.3 Analysis of RNA expression ...................................................................................... 39 3.2.4 Analysis of protein expression ................................................................................... 41 3.2.5 Functional assays ........................................................................................................ 44 3.2.6 Determination of methylation changes via Illumina EPIC 850k array ...................... 47 3.2.7 Assay for Transposase Accessible Chromatin with High Throughput Sequencing (ATAC-Seq) .......................................................................................................................... 48 3.2.8 CRISPR/dCas9-mediated targeted epigenetic editing experiments ........................... 48 3.2.9 Dataset Analysis ......................................................................................................... 55 3.2.10 Statistical Analysis .................................................................................................. 56 3.2.11 Graphical Illustrations ............................................................................................. 56 4. Results .................................................................................................................................... 57 4.1 Part I: Elucidating the Role of GLYATL1 in Endocrine Therapy Resistant Breast Cancer... 57 4.1.1 Establishment and characterization of endocrine therapy resistant breast cancer cell lines .................................................................................................................................... 57 4.1.2 Profiling of resistant cell line repertoire ..................................................................... 60 4.1.3 Clinical Significance of GLYATL1 ............................................................................. 64 4.1.4 GLYATL1 as a novel gene in endocrine therapy resistance context ........................... 67 4.1.4.1 Effect of GLYATL1 knockdown on cell viability ................................................... 67 4.1.4.2 Effect of GLYATL1 overexpression on cell proliferation ..................................... 69 4.1.4.3 Effect of GLYATL1 overexpression on cell cycle ................................................. 72 4.1.4.4 Effect of GLYATL1 overexpression on apoptosis ................................................. 73 4.1.5 Investigating the role of GLYATL1 as a potential HAT............................................ 74 4.1.6 Regulation of GLYATL1 ............................................................................................. 81 4.1.6.1 Epigenetic Regulation ................................................................................................. 81 4.1.6.2 Regulation by HER2 ............................................................................................... 85 4.2 Part II: Establishing CRISPR/dCas9-mediated Epigenetic Editing Methodology to Modulate the Epigenetic Landscape of Endocrine Therapy Resistant Breast Cancer ................................. 89 4.2.1 CRISPR/dCas9-mediated targeted epigenetic editing ................................................ 89 5. Discussion ............................................................................................................................ 105 5.1 Validation of in vitro models ....................................................................................... 105 5.2 GLYATL1 depletion leads to partial re-sensitization to endocrine therapy conditions 106 5.3 GLYATL1 overexpression confers endocrine therapy resistance ............................... 107 5.4 GLYATL1 overexpression counteracts induction of cell cycle arrest and apoptosis in endocrine therapy-sensitive cells ............................................................................................ 107 5.5 GLYATL1 is involved in histone acetylation .............................................................. 108 5.6 GLYATL1 expression correlates with poor prognosis in breast cancer patients .......... 111 5.7 GLYATL1 expression is regulated by HER2 and luminal transcription factors ........... 112 5.8 GLYATL1 is regulated by methylation ......................................................................... 113 5.9 GLYATL1 as a link between metabolism and epigenetics .......................................... 115 5.10 CRISPR/dCas9-mediated epigenetic editing is effective in fine tuning target genes .. 116 5.11 Wnt signaling pathway: BAMBI –CD44 axis ............................................................... 119 5.12 Conclusions and Outlook ............................................................................................. 123 References ................................................................................................................................... 125 Abbreviations .............................................................................................................................
Load more

Recommended publications
  • KAT6A Amplifications Are Associated with Shorter Progression-Free Survival and Overall Survival in Patients with Endometrial Serous Carcinoma
    PLOS ONE RESEARCH ARTICLE KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma 1 2 2 2 2 Ozlen Saglam , Zhenya Tang , Guilin Tang , L. Jeffrey Medeiros , Gokce A. TorunerID * 1 Department of Surgical Pathology, Moffitt Cancer Center, Tampa, Florida, United States of America, 2 Department of Hematopathology, Section of Clinical Cytogenetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America * [email protected] a1111111111 a1111111111 Abstract a1111111111 a1111111111 Somatic copy number alterations (CNA) are common in endometrial serous carcinoma a1111111111 (ESC). We used the Tumor Cancer Genome Atlas Pan Cancer dataset (TCGA Pan Can) to explore the impact of somatic CNA and gene expression levels (mRNA) of cancer-related genes in ESC. Results were correlated with clinico-pathologic parameters such as age of onset, disease stage, progression-free survival (PFS) and overall survival (OS) (n = 108). OPEN ACCESS 1,449 genes with recurrent somatic CNA were identified, observed in 10% or more tumor Citation: Saglam O, Tang Z, Tang G, Medeiros LJ, samples. Somatic CNA and mRNA expression levels were highly correlated (r> = 0.6) for Toruner GA (2020) KAT6A amplifications are 383 genes. Among these, 45 genes were classified in the Tier 1 category of Cancer associated with shorter progression-free survival and overall survival in patients with endometrial Genome Census-Catalogue of Somatic Mutations in Cancer. Eighteen of 45 Tier 1 genes serous carcinoma. PLoS ONE 15(9): e0238477. had highly correlated somatic CNA and mRNA expression levels including ARNT, PIK3CA, https://doi.org/10.1371/journal.pone.0238477 TBLXR1, ASXL1, EIF4A2, HOOK3, IKBKB, KAT6A, TCEA1, KAT6B, ERBB2, BRD4, Editor: JesuÂs Maria Paramio, CIEMAT, SPAIN KEAP1, PRKACA, DNM2, SMARCA4, AKT2, SS18L1.
    [Show full text]
  • A Set of Regulatory Genes Co-Expressed in Embryonic Human Brain Is Implicated in Disrupted Speech Development
    Molecular Psychiatry https://doi.org/10.1038/s41380-018-0020-x ARTICLE A set of regulatory genes co-expressed in embryonic human brain is implicated in disrupted speech development 1 1 1 2 3 Else Eising ● Amaia Carrion-Castillo ● Arianna Vino ● Edythe A. Strand ● Kathy J. Jakielski ● 4,5 6 7 8 9 Thomas S. Scerri ● Michael S. Hildebrand ● Richard Webster ● Alan Ma ● Bernard Mazoyer ● 1,10 4,5 6,11 6,12 13 Clyde Francks ● Melanie Bahlo ● Ingrid E. Scheffer ● Angela T. Morgan ● Lawrence D. Shriberg ● Simon E. Fisher 1,10 Received: 22 September 2017 / Revised: 3 December 2017 / Accepted: 2 January 2018 © The Author(s) 2018. This article is published with open access Abstract Genetic investigations of people with impaired development of spoken language provide windows into key aspects of human biology. Over 15 years after FOXP2 was identified, most speech and language impairments remain unexplained at the molecular level. We sequenced whole genomes of nineteen unrelated individuals diagnosed with childhood apraxia of speech, a rare disorder enriched for causative mutations of large effect. Where DNA was available from unaffected parents, CHD3 SETD1A WDR5 fi 1234567890();,: we discovered de novo mutations, implicating genes, including , and . In other probands, we identi ed novel loss-of-function variants affecting KAT6A, SETBP1, ZFHX4, TNRC6B and MKL2, regulatory genes with links to neurodevelopment. Several of the new candidates interact with each other or with known speech-related genes. Moreover, they show significant clustering within a single co-expression module of genes highly expressed during early human brain development. This study highlights gene regulatory pathways in the developing brain that may contribute to acquisition of proficient speech.
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
    [Show full text]
  • De Novo Nonsense Mutations in KAT6A, a Lysine
    Please cite this article in press as: Arboleda et al., De Novo Nonsense Mutations in KAT6A, a Lysine Acetyl-Transferase Gene, Cause a Syn- drome Including Microcephal..., The American Journal of Human Genetics (2015), http://dx.doi.org/10.1016/j.ajhg.2015.01.017 REPORT De Novo Nonsense Mutations in KAT6A, a Lysine Acetyl-Transferase Gene, Cause a Syndrome Including Microcephaly and Global Developmental Delay Valerie A. Arboleda,1 Hane Lee,1 Naghmeh Dorrani,2 Neda Zadeh,3,4 Mary Willis,5 Colleen Forsyth Macmurdo,6 Melanie A. Manning,6,7 Andrea Kwan,6,8 Louanne Hudgins,6 Florian Barthelemy,9 M. Carrie Miceli,9 Fabiola Quintero-Rivera,1 Sibel Kantarci,1 Samuel P. Strom,1 Joshua L. Deignan,1 UCLA Clinical Genomics Center,1 Wayne W. Grody,1,2,10 Eric Vilain,2,10 and Stanley F. Nelson1,10,* Chromatin remodeling through histone acetyltransferase (HAT) and histone deactylase (HDAC) enzymes affects fundamental cellular processes including the cell-cycle, cell differentiation, metabolism, and apoptosis. Nonsense mutations in genes that are involved in his- tone acetylation and deacetylation result in multiple congenital anomalies with most individuals displaying significant developmental delay, microcephaly and dysmorphism. Here, we report a syndrome caused by de novo heterozygous nonsense mutations in KAT6A (a.k.a., MOZ, MYST3) identified by clinical exome sequencing (CES) in four independent families. The same de novo nonsense mutation (c.3385C>T [p.Arg1129*]) was observed in three individuals, and the fourth individual had a nearby de novo nonsense mutation (c.3070C>T [p.Arg1024*]). Neither of these variants was present in 1,815 in-house exomes or in public databases.
    [Show full text]
  • Weighted Burden Analysis of Exome-Sequenced Case-Control Sample Implicates Synaptic Genes in Schizophrenia Aetiology
    Behavior Genetics (2018) 48:198–208 https://doi.org/10.1007/s10519-018-9893-3 ORIGINAL RESEARCH Weighted Burden Analysis of Exome-Sequenced Case-Control Sample Implicates Synaptic Genes in Schizophrenia Aetiology David Curtis1,2 · Leda Coelewij1 · Shou‑Hwa Liu1 · Jack Humphrey1,3 · Richard Mott1 Received: 22 November 2017 / Accepted: 13 March 2018 / Published online: 21 March 2018 © The Author(s) 2018 Abstract A previous study of exome-sequenced schizophrenia cases and controls reported an excess of singleton, gene-disruptive vari- ants among cases, concentrated in particular gene sets. The dataset included a number of subjects with a substantial Finnish contribution to ancestry. We have reanalysed the same dataset after removal of these subjects and we have also included non- singleton variants of all types using a weighted burden test which assigns higher weights to variants predicted to have a greater effect on protein function. We investigated the same 31 gene sets as previously and also 1454 GO gene sets. The reduced dataset consisted of 4225 cases and 5834 controls. No individual variants or genes were significantly enriched in cases but 13 out of the 31 gene sets were significant after Bonferroni correction and the “FMRP targets” set produced a signed log p value (SLP) of 7.1. The gene within this set with the highest SLP, equal to 3.4, was FYN, which codes for a tyrosine kinase which phosphorylates glutamate metabotropic receptors and ionotropic NMDA receptors, thus modulating their trafficking, subcellular distribution and function. In the most recent GWAS of schizophrenia it was identified as a “prioritized candidate gene”.
    [Show full text]
  • Mouse Kat6a Conditional Knockout Project (CRISPR/Cas9)
    https://www.alphaknockout.com Mouse Kat6a Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Kat6a conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Kat6a gene (NCBI Reference Sequence: NM_001081149 ; Ensembl: ENSMUSG00000031540 ) is located on Mouse chromosome 8. 18 exons are identified, with the ATG start codon in exon 3 and the TGA stop codon in exon 18 (Transcript: ENSMUST00000044331). Exon 4 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Kat6a gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-327N5 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Homozygous null mice display perinatal lethality, cyanosis, decreased hematopoietic progenitor cell numbers, and severely impaired spleen and thymus development, but are not anemic. Heterozygotes display strain background dependent reductions in fertility. Exon 4 starts from about 10.03% of the coding region. The knockout of Exon 4 will result in frameshift of the gene. The size of intron 3 for 5'-loxP site insertion: 40306 bp, and the size of intron 4 for 3'-loxP site insertion: 4429 bp. The size of effective cKO region: ~873 bp. The cKO region does not have any other known gene. Page 1 of 7 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 4 18 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Kat6a Homology arm cKO region loxP site Page 2 of 7 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats.
    [Show full text]
  • Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling Through TRIM24 Binding Deguan Lv1,2, Feng Jia3, Yanli Hou4, Youzhou Sang2, Angel A
    Published OnlineFirst October 11, 2017; DOI: 10.1158/0008-5472.CAN-17-1388 Cancer Tumor and Stem Cell Biology Research Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding Deguan Lv1,2, Feng Jia3, Yanli Hou4, Youzhou Sang2, Angel A. Alvarez5, Weiwei Zhang2, Wei-Qiang Gao2,BoHu5, Shi-Yuan Cheng2,5, Jianwei Ge3, Yanxin Li6, and Haizhong Feng2 Abstract Lysine acetyltransferase KAT6A is a chromatin regulator that PI3K/AKT signaling and tumorigenesis. Overexpressing activated contributes to histone modification and cancer, but the basis of its AKT or PIK3CA rescued the growth inhibition due to KAT6A actions are not well understood. Here, we identify a KAT6A silencing. Conversely, the pan-PI3K inhibitor LY294002 abrogat- signaling pathway that facilitates glioblastoma (GBM), where it ed the growth-promoting effect of KAT6A. Overexpression is upregulated. KAT6A expression was associated with GBM of KAT6A or TRIM24, but not KAT6A acetyltransferase activity– patient survival. KAT6A silencing suppressed cell proliferation, deficient mutants or TRIM24 mutants lacking H3K23ac-bind- cell migration, colony formation, and tumor development in an ing sites, promoted PIK3CA expression, AKT phosphorylation, orthotopic mouse xenograft model system. Mechanistic investi- and cell proliferation. Taken together, our results define gations demonstrated that KAT6A acetylates lysine 23 of histone an essential role of KAT6A in glioma formation, rationalizing H3 (H3K23), which recruits the nuclear receptor binding protein its candidacy as a therapeutic target for GBM treatment. TRIM24 to activate PIK3CA transcription, thereby enhancing Cancer Res; 77(22); 6190–201. Ó2017 AACR. Introduction deregulated in cancer, including glioma, partially due to aberrant histone modifications and mutations (2–4).
    [Show full text]
  • Transcriptional Regulators Are Upregulated in the Substantia Nigra
    Journal of Emerging Investigators Transcriptional Regulators are Upregulated in the Substantia Nigra of Parkinson’s Disease Patients Marianne Cowherd1 and Inhan Lee2 1Community High School, Ann Arbor, MI 2miRcore, Ann Arbor, MI Summary neurological conditions is an established practice (3). Parkinson’s disease (PD) affects approximately 10 Significant gene expression dysregulation in the SN and million people worldwide with tremors, bradykinesia, in the striatum has been described, particularly decreased apathy, memory loss, and language issues. Though such expression in PD synapses. Protein degradation has symptoms are due to the loss of the substantia nigra (SN) been found to be upregulated (4). Mutations in SNCA brain region, the ultimate causes and complete pathology are unknown. To understand the global gene expression (5), LRRK2 (6), and GBA (6) have also been identified changes in SN, microarray expression data from the SN as familial markers of PD. SNCA encodes alpha- tissue of 9 controls and 16 PD patients were compared, synuclein, a protein found in presynaptic terminals that and significantly upregulated and downregulated may regulate vesicle presence and dopamine release. genes were identified. Among the upregulated genes, Eighteen SNCA mutations have been associated with a network of 33 interacting genes centered around the PD and, although the exact pathogenic mechanism is cAMP-response element binding protein (CREBBP) was not confirmed, mutated alpha-synuclein is the major found. The downstream effects of increased CREBBP- component of protein aggregates, called Lewy bodies, related transcription and the resulting protein levels that are often found in PD brains and may contribute may result in PD symptoms, making CREBBP a potential therapeutic target due to its central role in the interactive to cell death.
    [Show full text]
  • Content Based Search in Gene Expression Databases and a Meta-Analysis of Host Responses to Infection
    Content Based Search in Gene Expression Databases and a Meta-analysis of Host Responses to Infection A Thesis Submitted to the Faculty of Drexel University by Francis X. Bell in partial fulfillment of the requirements for the degree of Doctor of Philosophy November 2015 c Copyright 2015 Francis X. Bell. All Rights Reserved. ii Acknowledgments I would like to acknowledge and thank my advisor, Dr. Ahmet Sacan. Without his advice, support, and patience I would not have been able to accomplish all that I have. I would also like to thank my committee members and the Biomed Faculty that have guided me. I would like to give a special thanks for the members of the bioinformatics lab, in particular the members of the Sacan lab: Rehman Qureshi, Daisy Heng Yang, April Chunyu Zhao, and Yiqian Zhou. Thank you for creating a pleasant and friendly environment in the lab. I give the members of my family my sincerest gratitude for all that they have done for me. I cannot begin to repay my parents for their sacrifices. I am eternally grateful for everything they have done. The support of my sisters and their encouragement gave me the strength to persevere to the end. iii Table of Contents LIST OF TABLES.......................................................................... vii LIST OF FIGURES ........................................................................ xiv ABSTRACT ................................................................................ xvii 1. A BRIEF INTRODUCTION TO GENE EXPRESSION............................. 1 1.1 Central Dogma of Molecular Biology........................................... 1 1.1.1 Basic Transfers .......................................................... 1 1.1.2 Uncommon Transfers ................................................... 3 1.2 Gene Expression ................................................................. 4 1.2.1 Estimating Gene Expression ............................................ 4 1.2.2 DNA Microarrays ......................................................
    [Show full text]
  • FOXP2 and Language Alterations in Psychiatric Pathology Salud Mental, Vol
    Salud mental ISSN: 0185-3325 Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz Castro Martínez, Xochitl Helga; Moltó Ruiz, María Dolores; Morales Marin, Mirna Edith; Flores Lázaro, Julio César; González Fernández, Javier; Gutiérrez Najera, Nora Andrea; Alvarez Amado, Daniel Eduardo; Nicolini Sánchez, José Humberto FOXP2 and language alterations in psychiatric pathology Salud mental, vol. 42, no. 6, 2019, pp. 297-308 Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz DOI: 10.17711/SM.0185-3325.2019.039 Available in: http://www.redalyc.org/articulo.oa?id=58262364007 How to cite Complete issue Scientific Information System Redalyc More information about this article Network of Scientific Journals from Latin America and the Caribbean, Spain and Journal's webpage in redalyc.org Portugal Project academic non-profit, developed under the open access initiative REVIEW ARTICLE Volume 42, Issue 6, November-December 2019 doi: 10.17711/SM.0185-3325.2019.039 FOXP2 and language alterations in psychiatric pathology Xochitl Helga Castro Martínez,1 María Dolores Moltó Ruiz,2,3 Mirna Edith Morales Marin,1 Julio César Flores Lázaro,4 Javier González Fernández,2 Nora Andrea Gutiérrez Najera,1 Daniel Eduardo Alvarez Amado,5 José Humberto Nicolini Sánchez1 1 Laboratorio de Genómica de Enfer- ABSTRACT medades Psiquiátricas y Neurode- generativas, Instituto Nacional de From the first reports of the linguist Noam Chomsky it has become clear that the development Medicina Genómica, Ciudad de Background. México, México. of language has an important genetic component. Several reports in families have shown the relationship 2 Departamento de Genética. Univer- between language disorders and genetic polymorphisms. The FOXP2 gene has been a fundamental piece sitat de València.
    [Show full text]
  • The Genetic Regulatory Signature of Type 2 Diabetes in Human Skeletal Muscle
    ARTICLE Received 17 Aug 2015 | Accepted 27 Apr 2016 | Published 29 Jun 2016 DOI: 10.1038/ncomms11764 OPEN The genetic regulatory signature of type 2 diabetes in human skeletal muscle Laura J. Scott1,*, Michael R. Erdos2,*, Jeroen R. Huyghe1,*, Ryan P. Welch1,*, Andrew T. Beck1, Brooke N. Wolford2, Peter S. Chines2, John P. Didion2, Narisu Narisu2, Heather M. Stringham1, D. Leland Taylor2,3, Anne U. Jackson1, Swarooparani Vadlamudi4, Lori L. Bonnycastle2, Leena Kinnunen5, Jouko Saramies6, Jouko Sundvall5, Ricardo D’Oliveira Albanus7, Anna Kiseleva7, John Hensley7, Gregory E. Crawford8,9, Hui Jiang1, Xiaoquan Wen1, Richard M. Watanabe10,11, Timo A. Lakka12,13,14, Karen L. Mohlke4, Markku Laakso15,16, Jaakko Tuomilehto17,18,19,20, Heikki A. Koistinen5,21,22, Michael Boehnke1,*, Francis S. Collins2,* & Stephen C.J. Parker7,23,* Type 2 diabetes (T2D) results from the combined effects of genetic and environmental factors on multiple tissues over time. Of the 4100 variants associated with T2D and related traits in genome-wide association studies (GWAS), 490% occur in non-coding regions, suggesting a strong regulatory component to T2D risk. Here to understand how T2D status, metabolic traits and genetic variation influence gene expression, we analyse skeletal muscle biopsies from 271 well-phenotyped Finnish participants with glucose tolerance ranging from normal to newly diagnosed T2D. We perform high-depth strand-specific mRNA-sequencing and dense genotyping. Computational integration of these data with epigenome data, including ATAC-seq on skeletal muscle, and transcriptome data across diverse tissues reveals that the tissue-specific genetic regulatory architecture of skeletal muscle is highly enriched in muscle stretch/super enhancers, including some that overlap T2D GWAS variants.
    [Show full text]
  • Food Allergy in a Child with De Novo KAT6A Mutation Varpu Elenius1*, Tuire Lähdesmäki2, Marja Hietala3 and Tuomas Jartti1
    Elenius et al. Clin Transl Allergy (2017) 7:19 DOI 10.1186/s13601-017-0155-x Clinical and Translational Allergy LETTER TO THE EDITOR Open Access Food allergy in a child with de novo KAT6A mutation Varpu Elenius1*, Tuire Lähdesmäki2, Marja Hietala3 and Tuomas Jartti1 Abstract Crying combined with miscellaneous gastrointestinal symptoms are typical symptoms of infant with food allergy, but are also common among children with abnormal neurological development. Mutations in KAT6A gene is known to cause a syndrome characterized by developmental delay, hypotonia, cardiac defects, microcephaly, specifc facial features and early feeding problems. However, these feeding problems have not earlier been specifed. We present the frst reported case of a DBPCFC confrmed food allergy in a child with KAT6A mutation whose feeding problems resolved with elimination diet. The present case does not establish proof of cause, but highlights the importance of careful clinical diagnostics despite other possible causes for feeding problems. Recognizing that early feeding prob‑ lems these patients regularly have might be caused by food allergy is important for outcome and quality of life for these patients. Keywords: Feeding problems, Food allergy, Histone acetylation, KAT6A mutation To the editor Case study Adverse reactions to food are a major clinical problem. Te patient was born at 39 weeks to non-consanquine- Te dermatologic and systemic reactions to food are well ous parents after uncomplicated pregnancy with normal recognized but reactions manifesting primarily in the maternal serum screening and ultrasounds. At birth, digestive tract can be difcult to recognize, diagnose and weight was 3.0 kg normal, length 46 cm (Z = −2.4) treat [1].
    [Show full text]